checkAd

    Aqua Bounty (Seite 6)

    eröffnet am 03.03.17 11:38:01 von
    neuester Beitrag 01.06.22 12:02:27 von
    Beiträge: 54
    ID: 1.247.982
    Aufrufe heute: 0
    Gesamt: 3.196
    Aktive User: 0

    ISIN: US03842K3095 · WKN: A3EUTZ
    1,7900
     
    EUR
    -6,77 %
    -0,1300 EUR
    Letzter Kurs 02.05.24 Lang & Schwarz

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    1,6600+32,80
    11,050+31,70
    38,22+28,00
    8,0000+26,66
    1,1400+20,00
    WertpapierKursPerf. %
    3,5000-26,24
    0,6700-26,58
    2,1300-34,41
    3,1600-38,64
    1,6300-51,49

    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 6

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 08.01.18 14:17:18
      Beitrag Nr. 4 ()
      Antwort auf Beitrag Nr.: 56.650.109 von R-BgO am 08.01.18 14:15:11
      aber, wer weiß...:
      https://www.welt.de/wissenschaft/article10010079/Der-Turbo-G…
      8 Antworten
      Avatar
      schrieb am 08.01.18 14:15:11
      Beitrag Nr. 3 ()
      Antwort auf Beitrag Nr.: 54.456.852 von R-BgO am 03.03.17 11:41:46
      ein paar Fortschritte gibt es:
      -im Juni hat man eine Fischfarm in Indiana(!) gekauft (https://aquabounty.gcs-web.com/news-releases/news-release-de…)

      -wie man der Bilanz

      entnehmen kann, ist ihnen irgendwann in 2017 eine KE gelungen; komischerweise finde ich kein Infos dazu

      -in den letzten Tage gab es einen Pop mit +150% an einem Tag und dann wieder rückwärts, was wohl etwas Interesse ausgelöst hat

      Insgesamt scheinen sie mir aber weiter eher "all talk, no action":
      http://www.proactiveinvestors.co.uk/companies/stocktube/8552…
      9 Antworten
      Avatar
      schrieb am 03.03.17 11:41:46
      Beitrag Nr. 2 ()
      Antwort auf Beitrag Nr.: 54.456.813 von R-BgO am 03.03.17 11:38:01
      nach langem Siechtum am AIM
      hat man Anfang 2017 wohl einen reverse-split plus KE gemacht und sich nun an der NASDAQ listen lassen:


      19 January 2017

      AquaBounty Technologies Inc.
      ("AquaBounty" or the "Company")

      Completion of NASDAQ Listing and Equity Subscription

      AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a biotechnology company focused on enhancing productivity in aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: XON) ("Intrexon"), announces that it has completed the listing of its common shares on the NASDAQ Stock Market and finalized the equity subscription from Intrexon.

      "AquaBounty's listing on NASDAQ represents an important milestone for the Company that will broaden our exposure to the U.S. markets as we advance plans for commercial production of our pioneering, environmentally responsible approach to fish farming," said Ronald L. Stotish, Ph.D., Chief Executive Officer of AquaBounty.

      "Aquaculture is the fastest-growing segment of food production globally, with estimates anticipating a doubling of farmed fish production by 2050. Commensurate with the industry's rapid growth, stresses on the oceans and new challenges resulting from open-sea cage farming are expected to rise. Our game-changing platform affords better economics for land-based aquaculture and all the advantages that it brings, including nutritious Atlantic salmon free of antibiotics, vaccines, and other treatments that are necessary to minimize infection in fish farming today," added Dr. Stotish.


      NASDAQ Listing

      Further to the Company's announcement of 7 November 2016 that it had filed a Form 10 registration statement (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") to register its Common Shares ("Common Shares") pursuant to Section 12(b) of the Securities Exchange Act of 1934, the Company now announces that it has completed the SEC review process and has received approval to list its Common Shares on NASDAQ.

      The Company's Common Shares will trade under the symbol AQB on NASDAQ commencing on 19 January 2017, and will continue to trade on AIM under the symbol ABTU.


      Equity Subscription

      The Company executed a share purchase agreement ("Share Purchase Agreement") with Intrexon on 7 November 2016 for the issuance and sale of 2,421,073 Common Shares (after the effect of the 1-for-30 reverse share split, the "Subscription Shares") raising $25.0 million (approximately £20.3 million) before expenses (the "Fundraising"). This equity subscription was conditional, inter alia, on admission of the Subscription Shares to trading on AIM ("Admission"), as well as the approval of the Company's listing on NASDAQ. Both of these conditions will be met today. The issue price of the Subscription Shares is 840 pence ($10.326, based on a conversion rate of £1:$1.2293) per share, which represents the closing price of the Company's Common Shares on AIM on 2 November 2016 (after the effect of the 1-for-30 reverse share split), which was the latest practical date for calculation prior to the approval of the transaction by AquaBounty's Independent Directors.


      Use of Proceeds

      As stated in the statement issued on 7 November 2016, the Fundraising will provide ongoing working capital and investment requirements to progress the Company's strategy over at least the next two years.

      Specifically, management is evaluating several paths to revenue generation that follow different timelines, including

      *production of AquAdvantage® fish at the Company's existing farm in Panama,

      *purchase of an existing production facility in North America, and

      * construction of a new production facility in North America.



      Share Distribution

      In conjunction with the completed listing of the Common Shares on NASDAQ and the Fundraising, Intrexon has distributed 1,776,557 of its holdings of Common Shares of AquaBounty (the "Distribution Shares") via a share dividend to its shareholders (the "Distribution"). This Distribution was completed to help AquaBounty satisfy certain listing requirements on NASDAQ for publicly held shares.


      Admission and Total Voting Rights

      The 2,421,073 Subscription Shares have been issued subject to Admission and will be credited as fully paid and will rank pari passu in all respects with the existing Common Shares. Admission of the Subscription Shares to trading on AIM is expected on 19 January 2017.

      Prior to the Fundraising and the Distribution, Intrexon held 4,516,731 Common Shares (representing 69.88% of the outstanding Common Shares). With the completion of the Fundraising and the issuance of the Subscription Shares and the distribution of the Distribution Shares, Intrexon now holds 5,161,247 Common Shares in the Company, representing 58.09% of the enlarged issued-share capital of 8,885,008 Common Shares. Each share carries the right to one vote, and therefore the total number of voting rights in the Company will be 8,885,008.
      10 Antworten
      Avatar
      schrieb am 03.03.17 11:38:01
      Beitrag Nr. 1 ()
      Zufallsfund:

      will genetisch veränderte Lachse vermarkten, pre revenue
      11 Antworten
      • 1
      • 6
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      +0,66
      +0,63
      +2,38
      +3,29
      +0,77
      +3,46
      +4,29
      +0,16
      +1,56
      -2,41

      Meistdiskutiert

      WertpapierBeiträge
      241
      100
      81
      74
      51
      49
      49
      37
      37
      33
      Aqua Bounty